Literature DB >> 8373714

Stereoselective disposition of (+/-)-sotalol at steady-state conditions.

C Fiset1, F Philippon, M Gilbert, J Turgeon.   

Abstract

The objective of this study was to assess, under steady-state conditions, the stereoselective disposition of (+/-)-sotalol in man. In all patients studied (n = 7) values of oral clearance (137 +/- 51 ml min-1), renal clearance (96 +/- 42 ml min-1) and nonrenal clearance (41 +/- 25 ml min-1) of (-)-sotalol were greater than those for (+)-sotalol (123 +/- 45 ml min-1, 89 +/- 39 ml min-1 and 34 +/- 23 ml min-1, respectively; P < 0.05, Student's paired t-test). Binding to plasma proteins was greater for (+)-sotalol (38 +/- 9% vs 35 +/- 9% for the (-)-enantiomer; P < 0.05) such that unbound oral clearance (+)/(-) ratio (0.95 +/- 0.06) and unbound renal clearance (+)/(-) ratio (0.97 +/- 0.06) were not stereoselective. In contrast, estimated unbound nonrenal clearance, which represents approximately 25% of the total unbound clearance of the drug, was greater for the (-)-enantiomer (64 +/- 42 ml min-1) compared with (+)-sotalol (57 +/- 42 ml min-1; P < 0.05). The difference in the pharmacokinetics of sotalol enantiomers is mainly related to stereoselectivity in plasma protein binding.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8373714      PMCID: PMC1364559          DOI: 10.1111/j.1365-2125.1993.tb05896.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

2.  Human pharmacokinetics of sotalol.

Authors:  M Anttila; M Arstila; M Pfeffer; R Tikkanen; V Vallinkoski; H Sundquist
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1976-07

3.  Electrophysiologial and beta-receptor blocking effects of MJ 1999 on dog and rabbit cardiac tissue.

Authors:  H C Strauss; J T Bigger; B F Hoffman
Journal:  Circ Res       Date:  1970-06       Impact factor: 17.367

Review 4.  Perspectives in adrenergic beta-receptor blockade.

Authors:  J D Fitzgerald
Journal:  Clin Pharmacol Ther       Date:  1969 May-Jun       Impact factor: 6.875

5.  Antiarrhythmic activity of the dextro- and levorotatory isomers of 4-(2-isopropylamino-1-hydroxyethyl) methanesulfonanilide (MJ 1999).

Authors:  P Somani; D L Watson
Journal:  J Pharmacol Exp Ther       Date:  1968-12       Impact factor: 4.030

6.  Comparative bioavailability and pharmacokinetics of sotalol administered alone and in combination with hydrochlorothiazide.

Authors:  H Sundquist; M Anttila; A Simon; J W Reich
Journal:  J Clin Pharmacol       Date:  1979 Aug-Sep       Impact factor: 3.126

7.  Studies on the pharmacokinetics and pharmacodynamics of the beta-adrenergic blocking agent sotalol in normal man.

Authors:  K Schnelle; G Klein; A Schinz
Journal:  J Clin Pharmacol       Date:  1979 Aug-Sep       Impact factor: 3.126

8.  Electrophysiological characterization of the class III activity of sotalol and its enantiomers. New interpretation of use-dependent effects.

Authors:  D Hafner; F Berger; U Borchard; A Kullmann; A Scherlitz
Journal:  Arzneimittelforschung       Date:  1988-02

9.  Electrophysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics.

Authors:  R Kato; N Ikeda; S M Yabek; R Kannan; B N Singh
Journal:  J Am Coll Cardiol       Date:  1986-01       Impact factor: 24.094

10.  The pharmacokinetics of d-sotalol and d,l-sotalol in healthy volunteers.

Authors:  J M Poirier; P Jaillon; B Lecocq; V Lecocq; A Ferry; G Cheymol
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

View more
  3 in total

Review 1.  Therapeutic drug monitoring: antiarrhythmic drugs.

Authors:  T J Campbell; K M Williams
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

Review 2.  Bioequivalence of chiral drugs. Stereospecific versus non-stereospecific methods.

Authors:  R Mehvar; F Jamali
Journal:  Clin Pharmacokinet       Date:  1997-08       Impact factor: 6.447

Review 3.  Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.

Authors:  A Fitton; E M Sorkin
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.